MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 329416 | Name: Perflutren

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Perflutren (also known as DMP-115, MRX-115, YM-454, and Aerosomes) is a drug used as ultrasound contrast medium and used to provide tamponade in the management of retinal detachment.

Chemical Structure

Perflutren
CAS#76-19-7

Theoretical Analysis

MedKoo Cat#: 329416

Name: Perflutren

CAS#: 76-19-7

Chemical Formula: C3F8

Exact Mass: 187.9872

Molecular Weight: 188.02

Elemental Analysis: C, 19.16; F, 80.84

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Perflutren; DMP-115; MRX-115; YM-454; DMP 115; MRX 115; YM 454; DMP115; MRX115; YM454; Aerosomes
IUPAC/Chemical Name
perfluoropropane
InChi Key
QYSGYZVSCZSLHT-UHFFFAOYSA-N
InChi Code
InChI=1S/C3F8/c4-1(5,2(6,7)8)3(9,10)11
SMILES Code
FC(F)(F)C(F)(F)C(F)(F)F
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 188.02 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Hauben M, Hung EY, Hanretta KC, Bangalore S, Snow V. Safety of Perflutren Ultrasound Contrast Agents: A Disproportionality Analysis of the US FAERS Database. Drug Saf. 2015 Nov;38(11):1127-39. doi: 10.1007/s40264-015-0332-6. PubMed PMID: 26242615. 2: Gupta A, Harris S, Naina H. Perflutren-Induced Angioedema. Echocardiography. 2015 Aug;32(8):1329. doi: 10.1111/echo.12971. PubMed PMID: 26192312. 3: Platts DG, McDonald C, Shekar K, Burstow DJ, Mullany D, Ziegenfuss M, Diab S, Fraser JF. Quantification of perflutren microsphere contrast destruction during transit through an ex vivo extracorporeal membrane oxygenation circuit. Intensive Care Med Exp. 2016 Dec;4(1):7. doi: 10.1186/s40635-016-0079-0. Epub 2016 Mar 11. PubMed PMID: 26969640; PubMed Central PMCID: PMC4788667. 4: Platts DG, Diab S, Dunster KR, Shekar K, Burstow DJ, Sim B, Tunbridge M, McDonald C, Chemonges S, Chan J, Fraser JF. Feasibility of perflutren microsphere contrast transthoracic echocardiography in the visualization of ventricular endocardium during venovenous extracorporeal membrane oxygenation in a validated ovine model. Echocardiography. 2015 Mar;32(3):548-56. doi: 10.1111/echo.12695. Epub 2014 Jul 24. PubMed PMID: 25059883. 5: Kalra A, Shroff GR, Erlien D, Gilbertson DT, Herzog CA. Perflutren-based echocardiographic contrast in patients with right-to-left intracardiac shunts. JACC Cardiovasc Imaging. 2014 Feb;7(2):206-7. doi: 10.1016/j.jcmg.2013.11.003. PubMed PMID: 24524748. 6: Platts DG, Luis SA, Roper D, Burstow D, Call T, Forshaw A, Pascoe R. The safety profile of perflutren microsphere contrast echocardiography during rest and stress imaging: results from an Australian multicentre cohort. Heart Lung Circ. 2013 Dec;22(12):996-1002. doi: 10.1016/j.hlc.2013.05.637. Epub 2013 Jun 10. PubMed PMID: 23764145. 7: Quiñones A, Benenstein R, Saric M. New-onset seizure after perflutren microbubble injection during dobutamine stress echocardiography. Echocardiography. 2013 Apr;30(4):E95-7. doi: 10.1111/echo.12149. Epub 2013 Feb 22. PubMed PMID: 23432576. 8: Goldberg YH, Ginelli P, Siegel R, Ostfeld RJ, Schaefer M, Spevack DM. Administration of perflutren contrast agents during transthoracic echocardiography is not associated with a significant increase in acute mortality risk. Cardiology. 2012;122(2):119-25. doi: 10.1159/000338731. Epub 2012 Jul 18. PubMed PMID: 22813648. 9: Sorrell VL, Ross WD, Kumar S, Kalra N. Left ventricular endocardial and epicardial border length delineation with perflutren contrast during transthoracic echocardiography. Echocardiography. 2011 Aug;28(7):761-6. doi: 10.1111/j.1540-8175.2011.01420.x. Epub 2011 May 12. PubMed PMID: 21564278. 10: Romagnuolo J, Hoffman B, Vela S, Hawes R, Vignesh S. Accuracy of contrast-enhanced harmonic EUS with a second-generation perflutren lipid microsphere contrast agent (with video). Gastrointest Endosc. 2011 Jan;73(1):52-63. doi: 10.1016/j.gie.2010.09.014. PubMed PMID: 21184870.